The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients with transitional cell carcinoma of the urothelium which failed or progressed after two lines of chemotherapy
Urothelial Cancer
DRUG: Everolimus (Afinitor®)
Progression-free survival rate at 12 weeks, If a patient has not had an event, Progression-free survival is censored at the date of last adequate tumor assessment., 3 months
A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients with transitional cell carcinoma of the urothelium which failed or progressed after two lines of chemotherapy